Long-term response rates to infliximab therapy for Crohn’s disease in an outpatient cohort

BACKGROUND: Infliximab’s efficacy in the induction and maintenance of remission in luminal Crohn’s disease has been confirmed by randomized, controlled trials. Less clearly described are long-term outcomes in the clinical practice setting since the establishment of regularly scheduled, every eight-w...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Teshima, Christopher W, Thompson, Adrienne, Dhanoa, LeRose, Dieleman, Levinus A, Fedorak, Richard N
Médium: Artigo
Jazyk:Inglês
Vydáno: Pulsus Group Inc 2009
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2706747/
https://ncbi.nlm.nih.gov/pubmed/19440565
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky